Vestcor Inc Sells 5,705 Shares of Lantheus Holdings, Inc. $LNTH

by · The Cerbat Gem

Vestcor Inc reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 31.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,334 shares of the medical equipment provider’s stock after selling 5,705 shares during the quarter. Vestcor Inc’s holdings in Lantheus were worth $821,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Parallel Advisors LLC raised its position in Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares during the last quarter. Vise Technologies Inc. purchased a new stake in Lantheus in the 4th quarter valued at $272,000. Reinhart Partners LLC. raised its position in Lantheus by 15.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after buying an additional 214,820 shares during the last quarter. Norges Bank purchased a new stake in Lantheus in the 4th quarter valued at $76,197,000. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in Lantheus in the 4th quarter valued at $95,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on LNTH shares. Truist Financial reissued a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Citizens Jmp increased their price target on Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research report on Friday, May 8th. JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Finally, William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.86.

View Our Latest Analysis on LNTH

Lantheus Trading Down 1.0%

Shares of Lantheus stock opened at $100.01 on Tuesday. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $104.00. The firm has a market cap of $6.51 billion, a PE ratio of 24.10 and a beta of -0.03. The stock has a fifty day moving average price of $88.48 and a 200-day moving average price of $75.44. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. During the same period last year, the firm posted $1.53 EPS. The business’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.42 EPS for the current year.

About Lantheus

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Featured Articles

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).